Cargando…
Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer
IMPORTANCE: Although bevacizumab has been used in the treatment of ovarian cancer, its optimal use is unknown. OBJECTIVE: To investigate time-dependent changes in the outcomes of bevacizumab therapy. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted using published data from 7 previ...
Autores principales: | Takamatsu, Shiro, Nakai, Hidekatsu, Yamaguchi, Ken, Hamanishi, Junzo, Mandai, Masaki, Matsumura, Noriomi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398412/ https://www.ncbi.nlm.nih.gov/pubmed/37531111 http://dx.doi.org/10.1001/jamanetworkopen.2023.26834 |
Ejemplares similares
-
Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
por: Takaya, Hisamitsu, et al.
Publicado: (2020) -
Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
por: Nakai, Hidekatsu, et al.
Publicado: (2023) -
CXCL13-producing CD4(+) T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer
por: Ukita, Masayo, et al.
Publicado: (2022) -
Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types
por: Takamatsu, Shiro, et al.
Publicado: (2021) -
Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types
por: Takamatsu, Shiro, et al.
Publicado: (2022)